Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Addiction treatment legislation

Executive Summary

House Commerce Committee Chairman Bliley (R-Va.) introduces "The Drug Addiction Treatment Act" July 30. The bill, a companion piece to Senate legislation (S 324) introduced in January by Sens. Hatch (R-Utah) and Levin (D-Mich.), would allow Schedule IV and V controlled substances for the treatment of addiction to be administered in a physician's office, allowing for wider distribution and application of drugs like Reckitt & Coleman's buprenorphine, which is pending approval at FDA (1"The Pink Sheet" March 15, p. 19)
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS034578

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel